Title
Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality.

Permalink
https://escholarship.org/uc/item/1638s9p8

Authors
Sharma, Ena
Pedersen, Brian
Terkeltaub, Robert

Publication Date
2019

DOI
10.1177/1179544119890853

Peer reviewed
Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality

Ena Sharma1,2, Brian Pedersen1,2 and Robert Terkeltaub1,2*

1Department of Medicine, San Diego Veterans Affairs Healthcare System, San Diego, CA, USA.
2Division of Rheumatology, Allergy & Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.

ABSTRACT

OBJECTIVE: The interleukin-1 (IL-1) receptor antagonist anakinra is an effective, off-label option in acute gout flares, when conventional therapy options are narrowed. We performed a retrospective, randomized, case-controlled study to gain clinical insight on baseline factors for gout patients most likely to receive anakinra, and ultimate mortality of those who received anakinra.

METHODS: Of 1451 gout patients seen between January 2003 and January 2015 in a Veterans Affairs (VA) rheumatology group practice, under stringent managed care principles, 13 (100% male), who received anakinra at least once for flares, were compared with 1:4 age- and sex-matched gout controls. Each patient’s first rheumatology encounter was studied by factor analysis for variables associated with later anakinra.

RESULTS: At baseline, patients that received anakinra had higher urate burden (palpable tophi [10/13] vs controls [16/52], P = .003), serum urate ([10.6 mg/dL] vs controls [7.6 mg/dL], P < .0001), and East Asian descent ([7/13] vs [16/52], P = .041). The anakinra group had higher ultimate all-cause mortality (6/13) vs controls (7/52), relative risk [RR] = 3.43, 95% confidence interval [CI] = 1.39-8.48, P = .0076). Factor analysis showed baseline visit palpable tophus and statin use to be most strongly associated with later anakinra use. Increased mortality of anakinra users, as per a factorial analysis, was linked more strongly to comorbidities than to anakinra.

CONCLUSIONS: At baseline rheumatology gout encounter, higher urate, palpable tophi, statin prescription, and East Asian descent were associated with later anakinra use for flares. Mortality was more closely associated to the presence of comorbidities at baseline rheumatology visit than to anakinra prescription.

KEYWORDS: Gout, hyperuricemia, arthritis, cytokines, mortality

Introduction

Gout is strongly associated with comorbidities, including obesity, metabolic syndrome, type II diabetes, hyperlipidemia, hypertension, chronic kidney disease (CKD), and coronary artery disease.1-3 Comorbidities frequently restrict conventional treatment options (ie, nonsteroidal anti-inflammatory drugs [NSAIDs], colchicine, corticosteroids) for gout flares.3 Acute gout flares are mediated by NLRP3 inflammassome activation with consequent interleukin-1β (IL-1β) release.4 Interleukin-1 (IL-1) antagonist, using the IL-1β-specific antibody canakinumab, is approved in Europe for gout flare. Off-label prescription of the soluble IL-1 receptor antagonist anakinra has been reported effective in case series,5-10 including in hospitalized inpatients.11-14 Anakinra was noninferior to conventional approved therapies for acute gouty arthritis in a recent controlled trial.15 To add insight, for clinical medicine, on baseline characteristics, and long-term mortality risk, in patients who ultimately received ≥1 rheumatologist-prescribed anakinra courses for acute gout, we conducted a randomized, case-control study.

Methods

We focused on a Veterans Affairs (VA) hospital group rheumatology practice, where anakinra pre-authorization was needed, with prescriptions limited to stringent managed care principles, for contraindication or failure of conventional acute gout therapies. VA San Diego Healthcare System Human Subjects Committee ethics board approved (#130245) the study of electronic records of 1451 patients fulfilling 2015 ACR/EULAR gout criteria,16 and seen by rheumatology between January 1, 2003 and January 27, 2015. All reviewed material was fully de-identified, retrospective information. A total of 13 patients received anakinra for gout flare, with demographics shown in Figure 1.

In retrospective case-control analyses, 4 age- and sex-matched controls were chosen (by randomization) for each patient who received anakinra (Figure 1). Control selection used search criteria in health records: gout diagnosis by International Classification of Diseases—Ninth Revision (ICD-9) coding, ≥1 visit to VA rheumatology clinic or inpatient rheumatology consultation, and

files/12/1/79544119890853/day1902f78248d51cbec170d97.jpg
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

1,451 patients with diagnosis of gout (21 females and 1,430 males) seen between January 1st 2003 and January 27th 2015 at a large VA rheumatology department

1 patient excluded (got anakinra for other reasons)
14 patients with anakinra use
13 patients with anakinra use for gout in study period
52 age and gender matched controls seen in study period

no recorded anakinra use. The first recorded rheumatology clinical encounter during the study period was analyzed. Gout flares were defined by validated criteria. Factor analysis of mixed data (FAMD), to explore similarities between all variables (quantitative and qualitative) for all individuals, was performed using FactoMineR (version 1.39) within the R environment (version 3.4.3). Relative risk (RR) was calculated as described by Altman.

Results

At initial rheumatology visit, patients ultimately receiving anakinra more frequently had palpable tophi and higher serum urate (Table 1). There were no significant differences in the mean

Figure 1. Flow diagram for patient selection and study design. VA indicates Veterans Affairs.

Table 1. Overview of demographics of patient populations and clinical profiles.

| ALL PATIENTS (N=65) | ANAKINRA GROUP (N=13) | CONTROL GROUP (AGE AND SEX MATCHED) (N=52) | P VALUE\(^a\) | P VALUE\(^b\) |
|---------------------|-----------------------|---------------------------------------------|--------------|--------------|
| Clinical profile    |                       |                                             |              |              |
| Palpable tophus detected, n (%) | 10/13 (77) | 16/52 (31) | .003 | .03 |
| Serum uric acid (mg/dL) | 10.66 | 7.65 | <.001 | .02 |
| Mean number of comorbidities | 3.92 | 3.18 | .112 | CI = –0.18 to 1.67 | .31 |
| Diabetes, n (%) | 7 (54) | 19 (37) | .35 | .58 |
| Hypertension, n (%) | 12 (93) | 39 (75) | .27 | .49 |
| CKD—stage 3 or greater, n (%) | 8 (62) | 13 (25) | .02 | .09 |
| CHF, n (%) | 4 (31) | 10 (20) | .45 | .71 |
| Obesity, n (%) | 8 (62) | 33 (64) | 1.00 | 1.00 |
| Ethnicity, n (%) |                       |                                             |              |              |
| Black | 1 (7) | 8 (15) | .67 | .87 |
| East Asian | 7 (54) | 16 (31) | .04 | .15 |
| White | 5 (39) | 29 (56) | 1.00 | 1.00 |
| Hispanic | 0 (0) | 4 (7) | .58 | .84 |
| Medications at baseline, n (%) |                       |                                             |              |              |
| Urate-lowering therapy | 7 (54) | 17 (33) | .21 | .45 |
| NSAIDs | 6 (47) | 26 (50) | 1.00 | 1.00 |
| Steroids | 3 (23) | 10 (20) | .72 | .87 |
| Colchicine | 8 (62) | 17 (33) | .11 | .31 |
| Metformin | 2 (16) | 6 (12) | .66 | .87 |
| Insulin | 3 (23) | 5 (10) | .20 | .45 |
| Loop diuretics | 4 (31) | 8 (16) | .24 | .47 |
| Statins | 9 (70) | 15 (29) | .01 | .08 |
| Thiazides | 1 (8) | 3 (6) | 1.00 | 1.00 |

Abbreviations: CHF, congestive heart failure; CI, confidence interval; CKD, chronic kidney disease; NSAIDs, nonsteroidal anti-inflammatory drugs.

Bold font for individual \( P \) values indicates statistical significance.

\(^a\)Uncorrected \( P \) values calculated using unpaired \( t \) tests.

\(^b\)\( P \) values corrected by the Benjamini-Hochberg procedure for multiple comparisons.
number of selected comorbidities (mean of 3.9 in anakinra, 3.1 in controls, \( P = .11 \), confidence interval [CI] = –0.18 to 1.67; Table 1), but ultimate all-cause mortality was greater in those who had received anakinra for acute flare ([6/13] vs controls [7/52], RR = 3.43, 95% CI = 1.39–8.48, \( P = .0076 \)). East Asian patients were more likely to be treated with anakinra (Table 1).

Most patients had several anakinra courses for gout flares and responded and tolerated anakinra well (not shown). Although the cause of death for several patients in the anakinra treatment group remains unknown, congestive heart failure (CHF) decompensation as precipitant was confirmed in 2 and septic shock (approximately 12 months from the last anakinra dose) in 1 who had received the most courses of anakinra (Table 2). By comparison, of 52 controls, 7 died during the study period (Table 2). Two patients were found dead at home and 3 died from complications of metastatic neoplasms. One with end-stage renal disease had a cardiac arrest during dialysis and 1 with neurogenic bladder died from renal failure, after declining dialysis.

Factor analysis of mixed data was applied to the qualitative variables shown in Figure 2, as well as estimated glomerular filtration rate (eGFR), total number of comorbidities per individual, and uric acid level (quantitative variables), for all individuals. Here, 35.51% of total variance of the data is represented within the first 2 dimensions. Eventual anakinra use was most strongly associated with baseline palpable tophus, and statin or urate-lowering therapy (ULT), which was exclusively allopurinol. There was distinct clustering, with either insulin or loop

| PATIENT | NUMBER OF COURSES OF ANAKINRA | RESPONSE TO ANAKINRA (DETERMINED BY TREATING PHYSICIAN) | SIDE EFFECTS | RE-FLARE IN 21 DAYS OR LESS | CAUSE OF DEATH, IF APPLICABLE |
|---------|-------------------------------|------------------------------------------------------|--------------|-----------------------------|-----------------------------|
| 1       | 3 courses (100mg/day × 5 days) | Excellent (complete and rapid response)              | None         | 1 repeat flare in 3 days after the first course. 1 repeat flare at 14 days after the second course | N/A                         |
| 2       | 1 course (100mg/d × 3 days)   | Substantial                                         | None         | Repeat flare at 7 days post cessation | N/A                         |
| 3       | 8 courses (100mg/d × 3-5 days) | Excellent                                            | Nonspecific malaise, dizziness | Minor flares at different sites within 14 days post cessation for the last 3 flares requiring anakinra Clostridium difficile infection, healthcare-associated pneumonia, renal failure | N/A                         |
| 4       | 1 course (100mg/d × 3 days)   | Excellent                                             | None         | Re-flare in 14 days post cessation | N/A                         |
| 5       | 1 course (100mg/d × 3 days)   | Lost to follow-up                                    | Lost to follow-up | Lost to follow-up | N/A                         |
| 6       | 1 course (100mg/d × 21 days)  | Excellent                                             | Injection site reaction | Re-flare in 14 days post cessation | N/A                         |
| 7       | 1 course (100mg/d × 5 days)   | Substantial                                           | None         | Flare still ongoing (but improved) at 21 days post anakinra | N/A                         |
| 8       | 1 course (100mg/d × 3 days)   | Excellent                                             | None         | Lost to follow-up | N/A                         |
| 9       | 1 course (100mg/d × 3 days)   | Substantial                                           | None         | Re-flare at different sites in <21 days post anakinra | Unknown                     |
| 10      | 1 course (100mg/d × 5 days)   | Poor                                                  | None         | No repeat flare within 21 days | CHF decompensation           |
| 11      | 2 courses (100mg/d × 3 days)  | Substantial                                           | None         | No repeat flare within 21 days | Unknown                     |
| 12      | 1 course (100mg/d × 14 days)  | Substantial                                           | Injection site reaction | No repeat flare within 21 days | CHF decompensation           |
| 13      | 1 course (100mg/d × 5 days)   | Excellent                                             | None         | No repeat flare within 21 days | Unknown                     |

Abbreviations: CHF, congestive heart failure; N/A, not applicable.
diuretic use, of death during the observation period (Figure 2). Increased mortality with antecedent anakinra prescription for acute gout essentially was linked strongly to comorbidities (Figure 2).

Discussion

Our study highlights that one of the strongest predictors of anakinra use for gout flare treatment is that other options are constrained by comorbidities. Patients requiring anakinra also were more likely to have greater serum urate elevation and tophaceous disease at baseline visit, East Asian descent, and, at the end of the observation period, higher mortality. Bevis et al\(^2\) identified 4 clusters in a cross section of gout comorbidity clustering: C1 (elderly with frequent gout attacks; 97% with CKD), C2 (isolated gout and frequent alcohol intake), C3 (hypertension, diabetes, hyperlipidemia, coronary heart disease, and/or CKD were most prevalent and this group had the highest frequency prescription of ULT), and C4 (obese and with hypertension). Here, anakinra recipients appeared to fall under cluster 3, with associated ULT and statin use. Gout is associated with premature mortality.\(^2\) Here, the death signal on factor analysis was tightly linked to insulin and loop diuretic use, thereby implicating comorbid diseases. Patients with more comorbidities, especially atherosclerosis, could have elevated systemic inflammation, potentially predisposing to more severe attacks of gout. Cardiovascular disease is more prevalent in gout than controls.\(^2\) Here, 22% of all patients had CHF and 81% had hypertension. East Asians (particularly Pacific Islanders) were disproportionately represented in anakinra recipients, but confounders and bias as well as low subject numbers may have contributed to this observation. Larger-scale studies would be indicated to identify and validate any potential genetic predisposition, such as by \textit{ABCG2} variant Q141K,\(^2\) to higher inflammatory state and comorbidities in gout.\(^2\)

Limitations of this study include that case-control studies have high susceptibility to bias, but performing the study in the same VA group was an effort to reduce such issues. A relatively complex VA patient population with prevalent comorbidities was examined, which, as in other VA-based studies, imposes contraindications to the use of NSAIDs, colchicine, or corticosteroids.\(^3\) Additional limitations included exclusively retrospective analyses, small sample size, men only receiving anakinra, and quite high prevalence of minority ethnic and racial groups.

In summary, the patient profile for anakinra prescription for acute gout was associated with specific characteristics at baseline rheumatology visit. These included uncontrolled hyperuricemia and a high body urate burden (reflected by palpable tophi), as well as East Asian descent, and a significantly increased number of comorbidities that could heighten systemic inflammation and predispose to continuing symptomatic gout. The increased all-cause mortality signal in this study, associated with prior use of anakinra for acute gout flare, was linked to higher comorbidity burden, especially cardiovascular disease.

Author Contributions

Each of the authors contributed to: Obtaining data, Interpreting data, writing and editing the manuscript.
Data Sharing

All final peer-reviewed manuscripts that arise from these data will be submitted to the digital archive PubMed Central. Wherever applicable, data will be deposited to appropriate public repositories (eg, dbGAP) or made available to investigators who request such information. De-identified data may be shared in the form of Excel spreadsheets, or in database or SAS dataset format. Documentation (data dictionary, etc) will be included to allow others to use the data.

ORCID iD
Robert Terkeltaub https://orcid.org/0000-0001-5368-7473

REFERENCES
1. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039-2052.
2. Igel TF, Krasnokutsky S, Pillinger MH. Recent advances in understanding and managing gout. F1000Res. 2017;6:247.
3. Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-163.
4. So A, Dumusc A, Nasi S. The role of IL-1 in gout: from bench to bedside. Rheumatology (Oxford). 2018;57:i12-i19.
5. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra’s efficacy is variable in refractory gout: a nationwide survey. Orphanet J Rare Dis. 2015;10:Article19.
6. Loustau C, Rosine N, Forien M, et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: a multicentre, retrospective study. Joint Bone Spine. 2018;85:755-760.